January 12-15 | San Francisco Marriott Marquis
January 12-16 | Virtual
Vyriad, Inc.
Privately-held clinical stage (phase 2) biotechnology company developing oncolytic virus-based cancer therapies and in vivo targeted delivery of genetic medicine (CAR-T) platforms.